S. Sharma, P. Gajowniczek, I. Way, D. Lee, J. Jiang et al., A common signaling cascade may underlie " addiction " to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell, pp.425-460, 2006.

J. Soria, T. Mok, F. Cappuzzo, and P. Jänne, EGFR-mutated oncogene-addicted nonsmall cell lung cancer: Current trends and future prospects, Cancer Treat Rev, 2012.
DOI : 10.1016/j.ctrv.2011.10.003

A. Shaw and J. Engelman, ALK in Lung Cancer: Past, Present, and Future, J Clin Oncol Mar, vol.1031, issue.8, pp.1105-1116, 2013.

H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer et al., Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia, New England Journal of Medicine, vol.346, issue.9, pp.645-52, 2002.
DOI : 10.1056/NEJMoa011573

F. Shepherd, R. Pereira, J. Ciuleanu, T. Tan, E. Hirsh et al., Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005.
DOI : 10.1056/NEJMoa050753

T. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

B. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., -Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014.
DOI : 10.1056/NEJMoa1408440

F. André, T. Bachelot, F. Commo, M. Campone, M. Arnedos et al., Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), The Lancet Oncology, vol.15, issue.3, pp.267-74, 2014.
DOI : 10.1016/S1470-2045(13)70611-9

C. Massard, S. Michiels, C. Ferté, M. Deley, L. Lacroix et al., High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discovery, vol.7, issue.6, pp.586-95, 2017.
DOI : 10.1158/2159-8290.CD-16-1396

L. Tourneau, C. Delord, J. Gonçalves, A. Gavoille, C. Dubot et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, pp.open-label

J. Gainor and A. Shaw, Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer, Journal of Clinical Oncology, vol.31, issue.31, pp.3987-96, 2013.
DOI : 10.1200/JCO.2012.45.2029

S. Kobayashi, T. Boggon, T. Dayaram, P. Jänne, O. Kocher et al., EGFR Mutation and Resistance of Non?Small-Cell Lung Cancer to Gefitinib, N Engl J Med Feb, vol.24352, issue.8, pp.786-92, 2005.

M. Arcila, G. Oxnard, K. Nafa, G. Riely, S. Solomon et al., Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, Clinical Cancer Research, vol.17, issue.5, pp.1169-80, 2011.
DOI : 10.1158/1078-0432.CCR-10-2277

L. Sequist, B. Waltman, D. Dias-santagata, S. Digumarthy, A. Turke et al., Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.105, issue.34, pp.75-101, 2011.
DOI : 10.1073/pnas.0803217105

H. Yu, M. Arcila, N. Rekhtman, C. Sima, M. Zakowski et al., Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers, Clinical Cancer Research, vol.19, issue.8, pp.2240-2247, 2013.
DOI : 10.1158/1078-0432.CCR-12-2246

P. Jänne, J. Yang, D. Kim, D. Planchard, Y. Ohe et al., AZD9291 in EGFR Inhibitor???Resistant Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1689-99, 2015.
DOI : 10.1056/NEJMoa1411817

T. Mok, Y. Wu, M. Ahn, M. Garassino, H. Kim et al., T790M???Positive Lung Cancer, New England Journal of Medicine, vol.376, issue.7, pp.629-669, 2017.
DOI : 10.1056/NEJMoa1612674

K. Thress, C. Paweletz, E. Felip, B. Cho, D. Stetson et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non???small cell lung cancer harboring EGFR T790M, Nature Medicine, vol.21, issue.6, pp.560-562, 2015.
DOI : 10.1158/0008-5472.CAN-07-1885

URL : http://europepmc.org/articles/pmc4771182?pdf=render

R. Katayama, T. Khan, C. Benes, E. Lifshits, H. Ebi et al., Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK, Proceedings of the National Academy of Sciences, vol.102, issue.21, pp.7535-7575, 2011.
DOI : 10.1073/pnas.0502860102

R. Katayama, A. Shaw, T. Khan, M. Mino-kenudson, B. Solomon et al., Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers, Science Translational Medicine, vol.67, issue.24, pp.120-137, 2012.
DOI : 10.1158/0008-5472.CAN-07-1885

J. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland et al., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, pp.1039-1082, 2007.

J. Bean, C. Brennan, J. Shih, G. Riely, A. Viale et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proceedings of the National Academy of Sciences, vol.11, issue.6, pp.20932-20939, 2007.
DOI : 10.1128/MCB.11.6.2962

J. Engelman and P. Janne, Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res, pp.2895-2904, 2008.

M. Niederst and J. Engelman, Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer. Sci Signal, pp.6-6, 2013.

C. Geyer, J. Forster, D. Lindquist, S. Chan, C. Romieu et al., Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.355, issue.26, pp.2733-2776, 2006.
DOI : 10.1056/NEJMoa064320

D. Solit and N. Rosen, Resistance to BRAF Inhibition in Melanomas, New England Journal of Medicine, vol.364, issue.8, pp.772-776, 2011.
DOI : 10.1056/NEJMcibr1013704

E. Van-allen, N. Wagle, A. Sucker, D. Treacy, C. Johannessen et al., The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discov, pp.94-109, 2014.

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39
DOI : 10.1056/NEJMoa1412690

URL : http://www.zora.uzh.ch/id/eprint/107163/1/Robert%20C%20et%20al.%20-%20N%20Engl%20J%20Med%202014.pdf

J. Larkin, P. Ascierto, B. Dréno, V. Atkinson, G. Liszkay et al., -Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014.
DOI : 10.1056/NEJMoa1408868

E. Van-allen, N. Wagle, P. Stojanov, D. Perrin, K. Cibulskis et al., Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nature Medicine, vol.27, issue.6, pp.682-690, 2014.
DOI : 10.1093/bioinformatics/btt085

A. Schram, D. Reales, J. Galle, R. Cambria, R. Durany et al., Oncologist Use and Perception of Large Panel Next Generation Tumor Sequencing]; Available from: https, Ann Oncol [Internet], 2017.

D. Robinson, Y. Wu, R. Lonigro, P. Vats, E. Cobain et al., Integrative clinical genomics of metastatic cancer, Nature, vol.12, issue.7667, pp.297-303, 2017.
DOI : 10.1038/nmeth.3412

Y. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima et al., EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors, New England Journal of Medicine, vol.363, issue.18, pp.1734-1743, 2010.
DOI : 10.1056/NEJMoa1007478

A. Shaw, L. Friboulet, I. Leshchiner, J. Gainor, S. Bergqvist et al., Resistance Mutation L1198F, New England Journal of Medicine, vol.374, issue.1, pp.54-61, 2016.
DOI : 10.1056/NEJMoa1508887

URL : http://europepmc.org/articles/pmc4773904?pdf=render

E. Kempf, L. Lacroix, and J. Soria, First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation, Clinical Lung Cancer, vol.16, issue.6, pp.259-61, 2015.
DOI : 10.1016/j.cllc.2015.06.002

D. Planchard, Y. Loriot, F. André, A. Gobert, N. Auger et al., EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients, Annals of Oncology, vol.31, issue.10, pp.2073-2081, 2015.
DOI : 10.1158/0008-5472.CAN-14-3167

S. Ortiz-cuaran, M. Scheffler, D. Plenker, D. L. Scheel, A. Fernandez-cuesta et al., Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors, Clinical Cancer Research, vol.22, issue.19, pp.4837-4884, 2016.
DOI : 10.1158/1078-0432.CCR-15-1915

A. Martinez-marti, E. Felip, J. Matito, E. Mereu, A. Navarro et al., Dual MET and ERBB inhibition overcomes intra-tumor plasticity in osimertinib resistant advanced non-small cell lung cancer (NSCLC) Ann Oncol [Internet], 2017.
DOI : 10.1093/annonc/mdx396

URL : https://academic.oup.com/annonc/article-pdf/28/10/2451/23066064/mdx396.pdf

Q. Huang, V. Schneeberger, N. Luetteke, C. Jin, R. Afzal et al., Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma, Molecular Cancer Therapeutics, vol.15, issue.10, pp.2521-2530, 2016.
DOI : 10.1158/1535-7163.MCT-16-0258

URL : http://europepmc.org/articles/pmc5289739?pdf=render

O. Gautschi, J. Milia, T. Filleron, J. Wolf, D. Carbone et al., Registry, Journal of Clinical Oncology, vol.35, issue.13, pp.1403-1413, 2017.
DOI : 10.1200/JCO.2016.70.9352

D. Falco, V. Buonocore, P. Muthu, M. Torregrossa, L. Basolo et al., Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.5, pp.811-820, 2013.
DOI : 10.1210/jc.2012-2672

G. Frampton, S. Ali, M. Rosenzweig, J. Chmielecki, X. Lu et al., Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors, Cancer Discovery, vol.5, issue.8, pp.850-859, 2015.
DOI : 10.1158/2159-8290.CD-15-0285

P. Paik, A. Drilon, P. Fan, H. Yu, N. Rekhtman et al., Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discov, pp.842-851, 2015.

L. Mahjoubi, A. Gazzah, B. Besse, L. Lacroix, and J. Soria, A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib, Investigational New Drugs, vol.5, issue.1, pp.397-405
DOI : 10.1016/j.cllc.2015.01.009

D. Camidge, S. Ou, G. Shapiro, G. Otterson, L. Villaruz et al., Efficacy and safety of crizotinib in patients with advanced c-METamplified non-small cell lung cancer (NSCLC), J Clin Oncol, vol.32, pp.8001-8001, 2014.

S. Waqar, D. Morgensztern, and J. Sehn, MET Mutation Associated with Responsiveness to Crizotinib, Journal of Thoracic Oncology, vol.10, issue.5, pp.29-31
DOI : 10.1097/JTO.0000000000000478

URL : https://doi.org/10.1097/jto.0000000000000478

M. Benderra, S. Aspeslagh, S. Postel-vinay, L. Bigot, D. Baere et al., Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor, Journal of Thoracic Oncology, vol.11, issue.2, pp.21-24, 2016.
DOI : 10.1016/j.jtho.2015.08.001

F. Facchinetti, Y. Loriot, M. Kuo, L. Mahjoubi, L. Lacroix et al., Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers, Clinical Cancer Research, vol.22, issue.24, pp.5983-91, 2016.
DOI : 10.1158/1078-0432.CCR-16-0917

K. Davies, A. Le, M. Theodoro, M. Skokan, D. Aisner et al., Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. Clin Cancer Res, pp.4570-4579, 2012.
DOI : 10.1158/1078-0432.ccr-12-0550

URL : http://clincancerres.aacrjournals.org/content/clincanres/18/17/4570.full.pdf

K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata et al., RET, ROS1 and ALK fusions in lung cancer, Nature Medicine, vol.344, issue.3, pp.378-81, 2012.
DOI : 10.1158/0008-5472.CAN-08-2014

K. Bergethon, A. Shaw, I. Ou, S. Katayama, R. Lovly et al., Rearrangements Define a Unique Molecular Class of Lung Cancers, Journal of Clinical Oncology, vol.30, issue.8, pp.863-70, 2012.
DOI : 10.1200/JCO.2011.35.6345

A. Shaw, S. Ou, Y. Bang, D. Camidge, B. Solomon et al., -Rearranged Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.371, issue.21, pp.1963-71, 2014.
DOI : 10.1056/NEJMoa1406766

A. Drilon, R. Somwar, J. Wagner, N. Vellore, C. Eide et al., A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer, Clinical Cancer Research, vol.22, issue.10, pp.2351-2359, 2016.
DOI : 10.1158/1078-0432.CCR-15-2013

T. Helsten, S. Elkin, E. Arthur, B. Tomson, J. Carter et al., The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res, pp.259-67, 2016.

R. Dienstmann, J. Rodon, A. Prat, J. Perez-garcia, B. Adamo et al., Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors, Annals of Oncology, vol.3, issue.3, pp.552-63, 2014.
DOI : 10.1158/2159-8290.CD-12-0362

M. Herrera-abreu, A. Pearson, J. Campbell, S. Shnyder, M. Knowles et al., Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer. Cancer Discov, pp.1058-71, 2013.
DOI : 10.1158/2159-8290.cd-12-0569

URL : http://cancerdiscovery.aacrjournals.org/content/candisc/3/9/1058.full.pdf

H. Davies, G. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002.
DOI : 10.1016/S0960-9822(97)70094-0

P. Paik, M. Arcila, M. Fara, C. Sima, V. Miller et al., Mutations, Journal of Clinical Oncology, vol.29, issue.15, pp.2046-51, 2011.
DOI : 10.1200/JCO.2010.33.1280

S. Cardarella, A. Ogino, M. Nishino, M. Butaney, J. Shen et al., Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.16, pp.4532-4572, 2013.
DOI : 10.1158/1078-0432.CCR-13-0657

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016.
DOI : 10.1016/S0140-6736(16)00004-0

D. Planchard, B. Besse, H. Groen, P. Souquet, E. Quoix et al., Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, The Lancet Oncology, vol.17, issue.7, pp.984-93, 2016.
DOI : 10.1016/S1470-2045(16)30146-2

H. Yang, D. Ye, K. Guan, and Y. Xiong, IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clin Cancer Res, pp.5562-71, 2012.
DOI : 10.1158/1078-0432.ccr-12-1773

URL : http://clincancerres.aacrjournals.org/content/clincanres/18/20/5562.full.pdf

C. Yun, K. Mengwasser, A. Toms, M. Woo, H. Greulich et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proceedings of the National Academy of Sciences, vol.60, issue.Pt 8, pp.2070-2075, 2008.
DOI : 10.1107/S0907444904011679

N. Katakami, S. Atagi, K. Goto, T. Hida, T. Horai et al., LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non???Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both, Journal of Clinical Oncology, vol.31, issue.27, pp.3335-3376, 2013.
DOI : 10.1200/JCO.2012.45.0981

M. Schuler, J. Yang, K. Park, J. Kim, J. Bennouna et al., Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial, Annals of Oncology, vol.32, issue.(Suppl. 15), pp.417-440, 2016.
DOI : 10.1158/2159-8290.CD-14-0326

D. Cross, S. Ashton, S. Ghiorghiu, C. Eberlein, C. Nebhan et al., AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov, pp.1046-61, 2014.

G. Oxnard, The cellular origins of drug resistance in cancer, Nature Medicine, vol.22, issue.3, pp.232-236, 2016.
DOI : 10.1038/nm.3854

A. Hata, M. Niederst, H. Archibald, M. Gomez-caraballo, F. Siddiqui et al., Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nature Medicine, vol.22, issue.3, pp.262-271
DOI : 10.1038/ng1180

URL : http://www.nature.com/nm/journal/v22/n3/pdf/nm.4040.pdf

M. Ramirez, S. Rajaram, R. Steininger, D. Osipchuk, M. Roth et al., Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nature Communications, vol.27, p.10690
DOI : 10.1093/bioinformatics/btr462

URL : http://www.nature.com/articles/ncomms10690.pdf

H. Yu, S. Tian, A. Drilon, L. Borsu, G. Riely et al., Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor, JAMA Oncology, vol.1, issue.7, p.982, 2015.
DOI : 10.1001/jamaoncol.2015.1066

URL : http://oncology.jamanetwork.com/data/journals/oncology/934521/cld150006.pdf

M. Niederst, H. Hu, H. Mulvey, E. Lockerman, A. Garcia et al., The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies, Clinical Cancer Research, vol.21, issue.17, pp.3924-3957, 2015.
DOI : 10.1158/1078-0432.CCR-15-0560

J. Remon and B. Besse, Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options, ESMO Open, vol.1, issue.4, p.81, 2016.
DOI : 10.1136/esmoopen-2016-000081

S. Peters, D. Camidge, A. Shaw, S. Gadgeel, J. Ahn et al., -Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017.
DOI : 10.1056/NEJMoa1704795

L. Friboulet, N. Li, R. Katayama, C. Lee, J. Gainor et al., The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer. Cancer Discov, pp.662-73, 2014.

H. Zou, L. Friboulet, D. Kodack, L. Engstrom, Q. Li et al., PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models, Cancer Cell, vol.28, issue.1, pp.70-81
DOI : 10.1016/j.ccell.2015.05.010

URL : https://doi.org/10.1016/j.ccell.2015.05.010

C. Lovly and W. Pao, Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance, Science Translational Medicine, vol.3, issue.75, pp.120-122
DOI : 10.1126/scitranslmed.3002003

J. Gainor, A. Varghese, S. Ou, S. Kabraji, M. Awad et al., ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.15, pp.4273-81, 2013.
DOI : 10.1158/1078-0432.CCR-13-0318

H. Ji, Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy, Cancer Science, vol.4, issue.9, pp.1933-1941, 2010.
DOI : 10.1038/nrc1300

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01629.x/pdf

A. Turke, K. Zejnullahu, Y. Wu, Y. Song, D. Dias-santagata et al., Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell, pp.77-88, 2010.

S. Kim, H. Kim, M. Yun, H. Kang, K. Pyo et al., Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis, p.241, 2016.

F. Malchers, M. Ercanoglu, D. Schütte, R. Castiglione, V. Tischler et al., -Amplified Lung Cancer, Clinical Cancer Research, vol.23, issue.18, 2017.
DOI : 10.1158/1078-0432.CCR-17-0478

K. Takezawa, V. Pirazzoli, M. Arcila, C. Nebhan, X. Song et al., Mutation, Cancer Discovery, vol.2, issue.10, pp.922-955, 2012.
DOI : 10.1158/2159-8290.CD-12-0108

J. Engelman, T. Mukohara, K. Zejnullahu, E. Lifshits, A. Borras et al., Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, Journal of Clinical Investigation, vol.116, issue.10, pp.2695-706, 2006.
DOI : 10.1172/JCI28656DS1

T. Sasaki, J. Koivunen, A. Ogino, M. Yanagita, S. Nikiforow et al., A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors, Cancer Research, vol.71, issue.18, pp.6051-60, 2011.
DOI : 10.1158/0008-5472.CAN-11-1340

URL : http://cancerres.aacrjournals.org/content/canres/71/18/6051.full.pdf

K. Ohashi, L. Sequist, M. Arcila, T. Moran, J. Chmielecki et al., Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proceedings of the National Academy of Sciences, vol.3, issue.1-2, pp.2127-2160, 2012.
DOI : 10.1242/dmm.003681

E. De-bruin, C. Cowell, P. Warne, M. Jiang, R. Saunders et al., Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discov, pp.606-625, 2014.

S. Sharma, D. Lee, B. Li, M. Quinlan, F. Takahashi et al., A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations, Cell, vol.141, issue.1, pp.69-80, 2010.
DOI : 10.1016/j.cell.2010.02.027

A. Cortot, C. Repellin, T. Shimamura, M. Capelletti, K. Zejnullahu et al., Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway, Cancer Research, vol.73, issue.2, pp.834-877, 2013.
DOI : 10.1158/0008-5472.CAN-12-2066

H. Terai, K. Soejima, H. Yasuda, S. Nakayama, J. Hamamoto et al., Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC, Molecular Cancer Research, vol.11, issue.7, pp.759-67, 2013.
DOI : 10.1158/1541-7786.MCR-12-0652

Z. Zhang, J. Lee, L. Lin, V. Olivas, V. Au et al., Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nature Genetics, vol.88, issue.8, pp.852-60, 2012.
DOI : 10.2353/jmoldx.2010.090140

J. Datta, S. Damodaran, H. Parks, C. Ocrainiciuc, J. Miya et al., Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398, Molecular Cancer Therapeutics, vol.16, issue.4, pp.614-638
DOI : 10.1158/1535-7163.MCT-15-1010

URL : http://mct.aacrjournals.org/content/molcanther/16/4/614.full.pdf

J. Thiery, H. Acloque, R. Huang, and M. Nieto, Epithelial-Mesenchymal Transitions in Development and Disease, Cell, vol.139, issue.5, pp.871-90, 2009.
DOI : 10.1016/j.cell.2009.11.007

URL : https://doi.org/10.1016/j.cell.2009.11.007

S. Thomson, E. Buck, F. Petti, G. Griffin, E. Brown et al., Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non???Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition, Cancer Research, vol.65, issue.20, pp.9455-62, 2005.
DOI : 10.1158/0008-5472.CAN-05-1058

R. Yauch, Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients, Clinical Cancer Research, vol.11, issue.24, pp.8686-98, 2005.
DOI : 10.1158/1078-0432.CCR-05-1492

J. Rho, Y. Choi, J. Lee, B. Ryoo, I. Na et al., Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line, Lung Cancer, vol.63, issue.2, pp.219-245, 2009.
DOI : 10.1016/j.lungcan.2008.05.017

P. Grygielewicz, B. Dymek, A. Bujak, P. Gunerka, A. Stanczak et al., Epithelial???mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells, Gastric Cancer, vol.6, issue.7, pp.53-62, 2016.
DOI : 10.1097/JTO.0b013e318216ee52

S. Barr, S. Thomson, E. Buck, S. Russo, F. Petti et al., Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions, Clinical & Experimental Metastasis, vol.6, issue.5, pp.685-93, 2008.
DOI : 10.1111/j.1432-0436.2006.00075.x

URL : https://link.springer.com/content/pdf/10.1007%2Fs10585-007-9121-7.pdf

K. Vuoriluoto, H. Haugen, S. Kiviluoto, J. Mpindi, J. Nevo et al., Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by 6
DOI : 10.1038/onc.2010.509

URL : http://www.nature.com/onc/journal/v30/n12/pdf/onc2010509a.pdf

N. Alam, K. Gustafson, M. Ladanyi, M. Zakowski, A. Kapoor et al., Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung, Clinical Lung Cancer, vol.11, issue.5, pp.1-4, 2010.
DOI : 10.3816/CLC.2010.n.046

A. Faber, R. Corcoran, H. Ebi, L. Sequist, B. Waltman et al., BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discov, pp.352-65, 2011.

S. José-eneriz, E. Agirre, X. Jiménez-velasco, A. Cordeu, L. Martín et al., Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia, European Journal of Cancer, vol.45, issue.10, pp.1877-89, 2009.
DOI : 10.1016/j.ejca.2009.04.005

K. Ng, A. Hillmer, C. Chuah, W. Juan, T. Ko et al., A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nature Medicine, vol.63, issue.4, pp.521-529, 2012.
DOI : 10.1038/nature03556

E. Verdin and M. Ott, 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond, Nature Reviews Molecular Cell Biology, vol.18, issue.4, pp.258-64, 2014.
DOI : 10.1128/MCB.01245-07

J. Feng, Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells, Oncol Rep, 2013.

H. Terai, K. Soejima, H. Yasuda, T. Sato, K. Naoki et al., Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line, International Journal of Oncology, vol.46, issue.1, 2014.
DOI : 10.3892/ijo.2014.2733

J. Zaretsky, A. Garcia-diaz, D. Shin, H. Escuin-ordinas, W. Hugo et al., Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma, New England Journal of Medicine, vol.375, issue.9, pp.819-848, 2016.
DOI : 10.1056/NEJMoa1604958

P. Sharma, S. Hu-lieskovan, J. Wargo, and A. Ribas, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, vol.168, issue.4, pp.707-730, 2017.
DOI : 10.1016/j.cell.2017.01.017

URL : https://cloudfront.escholarship.org/dist/prd/content/qt5st231s3/qt5st231s3.pdf

L. Verlingue, L. Mahjoubi, S. Aspeslagh, M. Pedrero, G. Buzzatti et al., Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies, Cancer Research, vol.77, issue.13 Supplement, pp.1011-1011, 2013.
DOI : 10.1158/1538-7445.AM2017-1011

W. Hugo, J. Zaretsky, L. Sun, C. Song, B. Moreno et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016.
DOI : 10.1016/j.cell.2016.02.065

P. Chen, W. Roh, A. Reuben, Z. Cooper, C. Spencer et al., Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade, Cancer Discovery, vol.6, issue.8, pp.827-864, 2016.
DOI : 10.1158/2159-8290.CD-15-1545

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res, pp.1920-1928, 2017.

S. Kato, A. Goodman, V. Walavalkar, D. Barkauskas, A. Sharabi et al., Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate, Clin Cancer Res, p.3133, 2016.